RDY Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Dr. Reddy's Laboratories Limited 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | ₹14.31 |
| 52주 최고가 | ₹15.71 |
| 52주 최저가 | ₹12.19 |
| 베타 | 0.26 |
| 1개월 변동 | 5.22% |
| 3개월 변동 | 3.17% |
| 1년 변동 | -8.21% |
| 3년 변동 | 16.64% |
| 5년 변동 | -2.60% |
| IPO 이후 변동 | 1,316.83% |
최근 뉴스 및 업데이트
Recent updates
Seeking Alpha • Aug 04
Dr. Reddy's: Needs To Invest $0.95 To Produce $1 Of New Revenues
Summary Dr. Reddy’s Laboratories is in a late-cycle earnings phase, due to rising capital intensity and margin pressure despite revenue momentum. Profitability and free cash flow are under strain, with a $0.95 investment needed for every $1 of new sales, tying up cash and eroding corporate value. While RDY enjoys high margins and pricing power in generics, reinvestment needs remain high, and growth is modest at ~3% annually. Upcoming catalysts like semaglutide and abatacept launches are promising, but regulatory hurdles and capital efficiency must improve for a more bullish stance. Read the full article on Seeking AlphaSeeking Alpha • Jan 30
Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns
Summary Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs. Despite the anticipated Revlimid revenue drop, RDY's new product launches in biosimilars and GLP-1 segments are expected to offset losses, driving future growth. RDY's current P/E ratio of 17.7x is near historical lows; a conservative 23x PE, which is equal to the peer median and slightly lower than the median of the historical range. RDY's target price comes up ~55% higher than the current stock price using the 23x PE ratio and FY28 EPS estimates. Read the full article on Seeking AlphaSeeking Alpha • Aug 13
Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy
Summary Dr. Reddy's Laboratories stock has risen 29% since my last publication, with additional tailwinds from legislative changes and strong business momentum. The company's enduring competitive advantage as a generics pharmaceutical manufacturer produces abnormally high and persistent returns on capital. Quarterly insights show growth in U.S. generics, Europe, and India markets, with high-quality economic characteristics supporting $107/share intrinsic value. Read the full article on Seeking AlphaSeeking Alpha • Nov 29
Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements
Summary Dr. Reddy's Laboratories reports impressive financial results, with record-breaking sales and profitability in their recent quarter. The company shows strong growth in their India, North America, Europe, and Emerging Markets businesses. Dr. Reddy's focuses on innovation, geographic diversification, and responsible corporate practices for sustained success in the pharmaceutical industry. Read the full article on Seeking AlphaSeeking Alpha • Oct 27
Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook
Summary Generic pharmaceutical manufacturers could benefit from structural tailwinds and are attractive in the current market environment. Dr. Reddy's Laboratories Limited (RDY) has posted impressionable Q2 fiscal '24 results, supporting a long-term investment outlook. The data supports a buy over the mid to long-term horizon, with a potential short-term pullback as an attractive entry point. Read the full article on Seeking AlphaSeeking Alpha • Aug 23
Dr. Reddy's: Growth Supported By New Labels, Profitability
Summary Dr. Reddy's Laboratories stock remains an attractive long-term investment. The company's Q1 FY'24 earnings showed strong growth in total revenues and gross margins, driven by sales expansion in its generic business. RDY's growth is supported by manageable working capital and cash flows, allowing for sustainable expansion. Net-net, reiterate buy. Read the full article on Seeking AlphaSeeking Alpha • Jun 07
Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy
Summary Dr. Reddy's Laboratories Ltd. (RDY) remains an attractive investment due to its strong Q4 and FY'23 numbers, exposure to the Indian generics market, and consistent new product launches. RDY is well-positioned in the high-growth generics market, along with other favorable business economics. Findings suggest RDY stock could be a buy with a target price of $60/share. Read the full article on Seeking AlphaSeeking Alpha • Feb 16
Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy
Summary Growth in key emerging markets, including India and Russian footprint. Positive Q3 FY23 results with top–bottom line growth. Solid FCF conversion and returns on capital. Reinvesting into growth at high rates of return, sporting respectable valuations. Buy thesis supported by these points. Investment Summary Now that we're cemented into the new year our hunt for under-exploited names positioned at all points along the broad healthcare spectrum continues. In this vein, it's essential to get the 'theme' right, especially given the pace of new developments in the biopharma and med-tech domains. One emergent theme that's spurred up in the past 12–24 months has been the skew of distribution of generic drug volumes away from the U.S. towards Indian pharmaceutical companies. This is propelled by FDA regulatory/approval policies and U.S. patent roadblocks facing competing labels. On this front we turned to Dr. Reddy's Laboratories Ltd. (RDY) given its differentiated geographic exposure to generic pharmaceuticals. The firm's Q3 FY23 results [corresponding to Q4 CY22] resulted in strong top-line and core EBITDA growth and we've observed the company is reinvesting ~11% of post-tax earnings at good rates of return to fund its future growth initiatives. Specifically, we've observed several themes in RDY's growth engine that warrant a constructive view, including 1) investment into differentiated and speciality products; 2) exposure to key markets including India and Russia; 3) new investment into its 'Horizon 2' segments; 3) attractive returns on capital; 4) respectable valuation[s]. RDY guides to a long-term 25% EBITDA margin and c.25% long-term return on capital, and, per CEO Erez Israeli's language on the call "double-digit growth and no debt". Subsequently, our observations posit the company is well positioned to achieve these numbers. Net-net, rate buy, seeking objectives of $60–$64 at 21x forward P/E. Exhibit 1. RDY reinvestment into growth Data: RDY Q3 FY23' Investor Presentation RDY Q3 results analysis It was another period of top-bottom line growth for RDY highlighted by its exposure to key growth markets in India and other emerging markets. In particular, revenue at $880mm was a 27% YoY expansion and also 700bps up sequentially, underscored by upsides across the entire company's operating architecture. Looking at the numbers in greater detail, key observations include: Top-line growth accompanied core EBITDA of $238mm on a margin of 29%, above RDY's long-term growth forecasts. This is after a quarterly capital investment of $35mm. A 545bps decompression in gross margin to 59.2%, driven by more favourable product mix and the tail of growth from new product segments. The highlight was pharmaceutical services and active ingredients ("PSAI") gross margin at ~64.5%, in-line with internal estimates. As expected, the firm lost ~17 percentage points of leverage at the SG&A line, given its heavy reinvestment in growth opportunities and broader expense base with new launches. Despite this, the SG&A margin was ~240bps lower YoY at 26.6%. Related to point 3), the R&D investment came in to $58mm at ~7% of top-line sales. Again, this reflected further investment into its pipeline assets, but also reflected digitalization and marketing efforts as well. It pulled this down to earnings of $151mm and converted FCFF of $239mm from operating cash flow of $281mm, a growth of 21%. Turning our optics to the geographic highlights, the standout in our eyes was emerging markets led by its Russian exposure [Exhibit 2]. It launched 29 products in the quarter across its emerging market footprint, leading to 14% YoY expansion in emerging markets and YoY growth in Russia of 29% specifically. In an otherwise unaccessible segment of the market, this provides investors a unique entry to pharmaceuticals in this region. Noteworthy, upsides were realized on the back of biosimilars sales, replicating strong momentum in this segment. Exhibit 2. Data: RDY Q3 FY23' Investor Presentation Key support for the buy thesis is the firm's incremental profitability and returns on capital. Each remain a standout in the RDY investment debate. These trends continued into the last quarter and form quintessential data that must be extrapolated for forward estimates and valuation. Remember, a firm creates value when its ROIC exceeds the hurdle rate, and growth only requires a small reinvestment of post-tax earnings. Here we use rolling TTM periods for a wider look-back window from Q2 CY20'–Q4 CY22'. At the end of the company's third quarter, it realized ~19% TTM ROIC, in-line with historical averages. It's important to note that we recalibrated the company's accounting profits to reflect its investing and earning profile, by capitalizing R&D as an investment at a 12% p.a. amortization schedule. You'll note RDY is a long-term compounder of post-tax earnings, accumulating $4.8Bn in NOPAT and $3.3Bn in earnings over the timeframe listed above. The additional growth on these figures was $78mm and $192mm, respectively [Exhibit 3]. As part of its growth initiatives, the firm invested an additional $530mm to generate these numbers, in other words, it reinvested ~11% of NOPAT for the future growth [~16% of earnings]. Supporting the buy thesis, the incremental return on invested capital ("ROIIC") pulls to ~15% [36% for earnings], supporting the company's high distributions of cash to equity holders. Note, after reinvestment for growth, RDY's earnings growth rate was 5.8% over this period, aligned with the 3-year CAGR in its stock price. Looking ahead, this is critical information in understanding RDY's future growth expectations. We'd remind readers also demonstrates management's propensity to create shareholder value: c.16% reinvestment, for c.36% return, with 84% of earnings distributed as residual cash flows for equity holders. Exhibit 3. Note: EBITA and Intangibles reconciled to include R&D as investment versus OpEx; EBITA with 12% p.a. amortization schedule (Data: Author's LT ROIC analysis, RDY SEC Filings)Seeking Alpha • Jan 20
Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed
Dr. Reddy's Laboratories (NYSE:RDY) said it successfully completed the full set of DRL_RI, a potential biosimilar of Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) and Biogen's (BIIB) blockbuster drug Rituxan (rituximab), for filing in markets including the U.S., Europe and other regions. The Indian drugmaker said DRL_RI is being developed as a biosimilar of rituximab for various indications which include treatment of adults with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis. Dr. Reddy's noted that rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets. The company undertook further clinical studies — RI-01-003, RI-01-006 (FLINTER) and RI-01-007 — to meet regulatory requirements of highly regulated markets and is now preparing to file applications in the U.S. and EU and other regions globally. Dr. Reddy's added that it collaborating with its partner Fresenius Kabi, a unit of Fresenius Medical Care (FMS), to commercialize the biosimilar in the U.S. Dr. Reddy's plans to sell the product in Europe and other geographies directly.Seeking Alpha • Nov 07
Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue
Summary Dr. Reddy's Laboratories is seeing its push into the generics market bear some fruit. However, RDY is also seeing a 23% decline in sales in key segments, due to a drop-off in Sputnik vaccine sales. The decline of COVID related products and the refocusing to new generics has RDY reliant on product launches and dividends to provide shareholder value. Long term share price analysis and sales opportunities from recent generics shows RDY is slightly overvalued and a wait and see. Investment Summary Dr. Reddy's Laboratories (RDY) had large revenue growth in 2021 due to sales of its Sputnik COVID vaccine product offering. Over a million doses were administered in India. Now, after cancellations as well as a drop in demand for the vaccine internationally, RDY needs to refocus on new generics in order to keep pace with revenue targets. Shareholders should be excited but also wary of the success of these new generic launches and acquisitions. Company Recent Financial News RDY's involvement in the Sputnik COVID-19 vaccine in 2021 has boosted EPS, but now, RDY is trying to replace that revenue this year with it's other product segments. Recent profits shows a mixed offering. Gross profit margins rose to 59% in the latest quarter, compared with 53% from last year. Sales in the company's key North American market increased 48% this past quarter. 12% growth in consolidated net profit was reported in Q2 2022 compared to 2021, and revenues improved by 9%. Drilling down, their Global Generics business posted revenue that is +18%. Pharmaceutical Services and Active Ingredients revenue was however down 23%, and 'Others' revenue was down 63%. In the Global Generics segment, North America recorded revenue growth of 48%. The emerging Markets division saw a decrease of 6% since last year. Profit before tax was up 27% in Q2 from last year as well. Long Term Share Price Performance Based on the 5 year stock performance, RDY has generated a YTD gain of 55.27%. By benchmarking this performance against the S&P500, it has performed only slightly better than the S&P500, which has only generated a YTD gain of 50.39%. RDY Moving Averages, 50 vs 200 (Yahoo! Finance) RDY stock price has dropped below MA50 on 26, June 2021 and has stayed below it ever since. However, it is looking to cross the MA50 line if there is further upside to the price. Historically when the price drops below the MA200 line, there is a strong rebound shortly. When the stock price first drops below MA200 in February of 2022, there was still a rebound rally although it was not at the levels of 2020. This was partially due to negative macroeconomic headwinds, recession fears, rising interest rates and supply chain disruption. Currently, the stock price is nearing the MA200 line and if there is any retracement, it could be an opportunity to start a position once it dips below the MA200 line. Currently, RDY is trading at a forward P/E of 20+ which is slightly higher than the average forward PE of the healthcare industry of 15.1. However, this is warranted as the company has been paying a consistent dividend with a payout ratio of at least 15%. The company has also been growing their EPS consistently and even with the recent poor outlook of 2021 and 2022, their EPS and revenue did not miss outside of normal estimates. Hence, this would warrant a higher forward P/E ratio compared to the average healthcare industry. Financial Insights The EBITDA and profit margin has increased from 2018 while gross margin has maintained around the same for the past 5 years. This is a mixed sign as it shows the resilience of management and their ability to maintain cost, given the current supply chain and inflation headwinds that most company are facing, but also possible headwinds and a reliance on new products replacing older ones. Asset productivity has increased over the past 5 years, which shows that management is efficiently using their assets to generate return. Current ratio has increased which shows that there is sufficient liquidity in the balance sheet for management to repay all of their current liabilities if they choose to do so. Interest coverage ratio has also increased which means that management has reduced their debt leverage. RDY Financials (SEC Filing) EPS has increased steadily for the past 5 years, and overall, the company has shown some improvement in the past 5 years. Assuming a market risk premium to be 5.60%, the equity beta of RDY is 0.22. CAPM = 4.01% + (5.60% x 0.22) = 5.24%. Based on their annual report, the interest expense is $644m and the total debt borrowings is $21,711m. Cost of debt was 2.97%, and the equity financing ratio (E/V) was 0.75. The debt financing ratio (D/V) was 0.25. RDY Income Statement, Consolidated (SEC Filing) Dividend payout ratio has been 15%-25%, which is the average dividend payout ratio in the past 5 years. Although it has never reached a bottom of 15%, the outlook of the current macro economy is questionable, and it would be more prudent to forecast a lower dividend payout ratio in the worst case scenario. RDY cash on hand for 2022 was $0.61B. Revenue Insights and Near Term Price Takeaway RDY continues its push into the generics market in both its acquisitions as well as its licensing deals and new product launches. Most recently, RDY's first-to-launch generic versions of extended release antihistamines as well as sorafenib for the treatment of kidney and liver cancers has shown that RDY is pushing towards a broad lineup of generics. It has also increased it's pace of acquisitions and licenses, with Biorphen and related hypotension drugs as well as Lumify white labels for the treatment of eye redness. Off-loading it's non-generic portfolio continues, with I/ONTAK/e7777 coming to mind, an oncology drug focusing on CTCL and potentially PTCL that was a reformulation of a previously approved drug. Fexofenadine HCI and Pseuudoephedrine HCI extended release antihistamines are a generic drug replacement for Allegra-D 24 hr, which had U.S. retail sales of approximately $45 million as of May 2022. Sorafenib tablets are a generic replacement for Nexavar, which had over $750 million in sales in 2020. Cysteine hydrochloride injections are generics for Biorphen and Rezipres injections, with a total addressable market of $174 million in 2022. Brimonidine Tartrate ophthalmic solution, a generic to replace Lumify OTC eyedrops, has a total addressable market of $130 million in 2022. I/ONTAK/e7777 represents a total of $100+ million in one time payments once approved, with revenue share afterwards of an immediately addressable market of $330 million +/-. All told, with several acquisitions and new generic drugs coming online, RDY is hoping to capture part of $634 million in addressable markets as well as part of ~$800 million in ongoing sales from current brand name drug sales from the above generic launches. These represent the largest product launches that aren't hampered by legal action or FDA approval delays, and whose sales should help boost sales across segments to help meet the Sputnik vaccine shortfalls. Incorporating relatively conservative estimates of these sales of 10-20% in the near term as well as applying a margin of safety of 10%, the fair value of RDY would be around $49-$51 per share, in comparison to the current stock price of ~$54. Hence, RDY seems to be slightly overvalued at the moment. To fully capture income from these new generics, RDY needs at least 3-4 quarters to ramp up. Therefore, a higher than $54 share price is justified after sales are reflected of these new generics, assuming RDY is able to capture 40%+ of their addressable market and sales targets. Potential Outside Factors and Downside Risks Fluctuation of Commodity PriceSeeking Alpha • Jul 28
Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M
Dr. Reddy's press release (NYSE:RDY): Q1 GAAP EPS of $0.90. Revenue of $660M (+5.9% Y/Y) misses by $12.78M.Seeking Alpha • Jul 22
Dr. Reddy's launches generic drugs for allergies in US
Dr. Reddy's Laboratories Ltd. (NYSE:RDY) announced the first-to-market launch of over-the-counter (OTC) fexofenadine HCl 180 mg and pseudoephedrine HCl 240 mg extended release tablets, the store-brand equivalent of Allegra-D 24 HR in the U.S. market. The company said the drug is an oral antihistamine and nasal decongestant for temporary relief of nasal and sinus congestion due to colds or allergies.Seeking Alpha • Jul 05
Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases
Dr. Reddy's Laboratories said its unit Aurigene, and EQRx are collaborating to develop drug candidates for cancer and immune-inflammatory diseases. Under the agreement, Aurigene will use its small molecule drug discovery platform and will lead drug discovery and pre-clinical development efforts while EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts. The companies said they would share funding on development and any commercialization of potential drug candidates.주주 수익률
| RDY | US Pharmaceuticals | US 시장 | |
|---|---|---|---|
| 7D | 7.6% | 0.04% | -2.3% |
| 1Y | -8.2% | 38.9% | 21.2% |
수익률 대 산업: RDY은 지난 1년 동안 37.5%의 수익을 기록한 US Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: RDY은 지난 1년 동안 23.3%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| RDY volatility | |
|---|---|
| RDY Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: RDY는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: RDY의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1984 | 27,527 | Erez Israeli | www.drreddys.com |
닥터 레디 래버러토리스 리미티드는 자회사와 함께 북미, 유럽, 인도, 러시아 및 국제적으로 통합 제약 회사로 운영되고 있습니다. 이 회사는 글로벌 제네릭, 제약 서비스 및 활성 성분(PSAI), 기타 부문을 통해 사업을 운영하고 있습니다. 글로벌 제네릭 부문은 브랜드 이름으로 판매되거나 브랜드 제형과 치료적 동등성이 있는 제네릭 완제품으로 판매되는 처방약 및 일반의약품을 제조 및 판매하며 생물학적 제제 사업에도 참여하고 있습니다.
Dr. Reddy's Laboratories Limited 기초 지표 요약
| RDY 기초 통계 | |
|---|---|
| 시가총액 | US$11.44b |
| 순이익 (TTM) | US$452.46m |
| 매출 (TTM) | US$3.55b |
25.3x
주가수익비율(P/E)3.2x
주가매출비율(P/S)RDY는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| RDY 손익계산서 (TTM) | |
|---|---|
| 매출 | ₹335.93b |
| 매출원가 | ₹158.67b |
| 총이익 | ₹177.26b |
| 기타 비용 | ₹134.41b |
| 순이익 | ₹42.85b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Jul 22, 2026
| 주당순이익(EPS) | 51.46 |
| 총이익률 | 52.77% |
| 순이익률 | 12.76% |
| 부채/자본 비율 | 16.5% |
RDY의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
0.6%
현재 배당 수익률16%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/23 05:10 |
| 종가 | 2026/06/23 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Dr. Reddy's Laboratories Limited는 69명의 분석가가 다루고 있습니다. 이 중 37명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |